SCHEMBL2666682

SCHEMBL2666682

CCOC(=O)C(=O)c1ccc(SC2CC2)nc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
RAB9A P51151 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DGAT1 O75907 1/20 0.35
KMT2A Q03164 2/20 0.34
NPC1 O15118 1/20 0.34
ATM Q13315 1/20 0.33
POLB P06746 1/20 0.33
CXCR1 P25024 1/20 0.33
CXCR2 P25025 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2666994 0.82 MAPT (0.41) MAPTRAB9AALDH1A1CYP1A2CYP2C9
SCHEMBL2653679 0.81 RAB9A (0.34) MAPTDDB1CRBNRAB9AL3MBTL1
SCHEMBL2653678 0.81 RAB9A (0.34) MAPTDDB1CRBNRAB9AL3MBTL1
SCHEMBL11972279 0.80 HPGD (0.39) DDB1CRBNRAB9AL3MBTL1ALDH1A1
SCHEMBL185319 0.79 ALDH1A1 (0.42) MAPTRAB9AL3MBTL1ALDH1A1CYP1A2
SCHEMBL2654127 0.79 ALDH1A1 (0.46) DDB1CRBNRAB9AL3MBTL1ALDH1A1
SCHEMBL25254764 0.76 MAPK1 (0.57) MAPTDDB1CRBNRAB9AL3MBTL1
SCHEMBL4260216 0.75 HTT (0.39) MAPTRAB9AL3MBTL1ALDH1A1CYP1A2
SCHEMBL13033252 0.74 ALDH1A1 (0.38) MAPTRAB9AL3MBTL1ALDH1A1HPGD
SCHEMBL2666993 0.73 MAPT (0.41) MAPTRAB9AL3MBTL1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 US disclosed
WO-2007007886-A1 AN OXIME DERIVATIVE AND PREPARATIONS THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132479-A1 Oxime Derivative and Preparations Thereof GCK, KHK, GCKR MAPT 4489/4885DDB1 4661/4885CRBN 2242/4885
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF GCK, KHK, GCKR MAPT 4489/4885DDB1 4661/4885CRBN 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.